News headlines about Kadmon Holdings (NASDAQ:KDMN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kadmon Holdings earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.8903478320138 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Technical Watch – Kadmon Holdings, Inc. (KDMN) moves -67.54% off from One Year High – Voice Of Analysts (analystsbuzz.com)
- Kadmon Holdings, Inc. (KDMN) registers a price change of 7.87 … – Stocks Gallery (stocksgallery.com)
- Kadmon Holdings, Inc. (KDMN) Sentiment Based on the Technical … – StockNewsGazette (stocknewsgazette.com)
- Insider Selling: Kadmon Holdings Inc (KDMN) Major Shareholder Sells 302,950 Shares of Stock (americanbankingnews.com)
- Kadmon to Present at the Rodman & Renshaw 19 – Business Wire (press release) (businesswire.com)
KDMN has been the subject of a number of analyst reports. Zacks Investment Research downgraded Kadmon Holdings from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kadmon Holdings in a research note on Monday, June 26th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $7.00 price target on shares of Kadmon Holdings in a research note on Friday, July 14th. Finally, ValuEngine downgraded Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $8.92.
Kadmon Holdings (KDMN) opened at 3.12 on Wednesday. The firm’s market cap is $161.76 million. Kadmon Holdings has a 1-year low of $2.89 and a 1-year high of $8.28. The company has a 50-day moving average price of $2.97 and a 200-day moving average price of $3.55.
Kadmon Holdings (NASDAQ:KDMN) last issued its earnings results on Thursday, August 3rd. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.05. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.46 million. During the same quarter in the prior year, the business earned ($4.40) EPS. The firm’s revenue for the quarter was down 53.1% compared to the same quarter last year. On average, equities research analysts forecast that Kadmon Holdings will post ($1.58) EPS for the current fiscal year.
In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 349,661 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $2.60, for a total value of $909,118.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders acquired 14,707 shares of company stock valued at $34,294 and sold 2,143,281 shares valued at $7,020,661.
WARNING: This report was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thestockobserver.com/2017/09/13/kadmon-holdings-kdmn-earns-media-impact-score-of-0-21.html.
About Kadmon Holdings
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.